...
首页> 外文期刊>International urogynecology journal and pelvic floor dysfunction >Urethral injection for stress urinary incontinence: long-term results with dextranomer/hyaluronic acid copolymer.
【24h】

Urethral injection for stress urinary incontinence: long-term results with dextranomer/hyaluronic acid copolymer.

机译:尿道注射治疗压力性尿失禁:葡聚糖/透明质酸共聚物的长期疗效。

获取原文
获取原文并翻译 | 示例
           

摘要

Urethral injection is a convenient, minimally invasive means of treating stress urinary incontinence (SUI). We present long-term follow-up data from 20 patients originally recruited in 1994-95 (mean age 67 years) to receive urethral injection with dextranomer/hyaluronic acid (Dx/HA) copolymer. The majority of patients had failed previous therapy for SUI. If the first injection was unsuccessful, up to two further injections were offered. Only 3 patients (15%) failed to show a response to treatment. Sixteen women were reassessed during 2001 (4 had died of causes unrelated to the study treatment). A sustained response throughout the follow-up period was reported in 9/16 patients (57%), with incontinence recurring in just 4 (25%). None of the 7 patients with persistent or recurrent incontinence were cured by subsequent treatments, including surgery. In conclusion, urethral injection with Dx/HA copolymer offers promising long-term efficacy in the treatment of SUI, regardless of old age or failure to respondto previous therapy.
机译:尿道注射是一种治疗压力性尿失禁(SUI)的便捷,微创手段。我们提供了1994年至95年(平均年龄67岁)最初招募的接受右旋糖酐/透明质酸(Dx / HA)共聚物尿道注射的20例患者的长期随访数据。大多数患者先前的SUI治疗失败。如果第一次注射失败,则最多可以再注射两次。只有3例患者(15%)对治疗无反应。 2001年重新评估了16名妇女(其中4名死于与研究治疗无关的原因)。据报道,在整个随访期间,有9/16例患者(57%)持续缓解,仅4例(25%)尿失禁复发。 7例持续性或复发性尿失禁患者均未通过后续治疗(包括手术)治愈。总之,尿道注射Dx / HA共聚物可在SUI的治疗中提供有希望的长期疗效,无论年龄大或对以前的治疗没有反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号